PPT-EMPEROR-Reduced Trial Effect of Empagliflozin on Cardiovascular

and Renal Events in Heart Failure With a Reduced Ejection Fraction Milton Packer MD and Faiez Zannad MD on behalf of the EMPERORReduced Executive Committee Trial Committees Investigators and Coordinators. This study compared cardiovascular safety pro64257les of 2 local anesthetics LA articaine Ubistesine versus standard lidocaine solution in cardiovascular patients Study design Fifty cardiovascular patients were randomly assigned to dental treatment Modified Barium Swallow. Purpose. Define abnormalities in anatomy and physiology causing the patient’s symptoms. Identify and evaluate treatment strategies that may immediately enable the patient to eat safely.. Silvio E Inzucchi. Professor of . Medicine. , . Yale University School of Medicine, New Haven, CT, USA. 1. Disclosure. Consultations. and non-. financial. support . Boehringer Ingelheim, Merck, Janssen, Novo Nordisk, Sanofi/Regeron, Intarcia, Lexicon, Poxel, Takeda, Eli Lilly. Program Overview. EMPA-REG OUTCOME: Trial Design. EMPA-REG OUTCOME: Primary Endpoint: 3-Point MACE*. EMPA-REG OUTCOME: CV Death . EMPA-REG OUTCOME: CV Death, . Nonfatal MI, and Nonfatal Stroke . EMPA-REG OUTCOME: . Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. This program will include a discussion of off-label treatment and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Diabetes Drugs Have Been Shown to Reduce CV Risk. University of Oxford, UK. Professor Chang Yu Pan Professor Da Yi Hu. . Chinese PLA General Hospital University of Peking. China China. Rationale for ACE Trial. Accumulating evidence suggests a close association between “prediabetes” and cardiovascular disease (CVD). Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. . Buse. , Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter . LABELING1HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TRIJARDYXR safely and effectively See full prescribing information for TRIJARDY TRIJARD Brian A. . Ference. MD, . MPhil. , . MSc. , John J. P. Kastelein MD, PhD, . Kausik. K. Ray MD, . MPhil. , Henry N. Ginsberg MD, M. John Chapman PhD, . DSc. , Chris J. Packard . DSc. , Ulrich . Laufs. Final Results. Background. Trends in the Prevalence of Complications among. US Adults with Newly Diagnosed Diabetes . Fang M & Selvin E . Diabetes Care . 2021;44:699-706 . 0.003. <0.001. 0.30. Dr Theingi Aung. Endocrinologist. Royal Berkshire Hospital. 12. th. Jan 2018. What would your ideal diabetes drug do?. Effective in lowering HbA1c. No . hypoglycaemia. No effect on weight/ weight loss?. Effects of Interleukin-6 Inhibition with . Ziltivekimab. on Biomarkers of Inflammation and Thrombosis Among Patients at High Atherosclerotic Risk:. A Randomized, Double-Blind Phase 2 Trial. . Paul Ridker, Matt Devalaraja, Florian Baeres, Mads Engelmann, G Kees Hovingh, Milana Ivkovic, Larry Lo, Douglas Kling, Pablo Pergola, Dominic Raj, Peter Libby, and Michael Davidson . Saidee Oberlander, PharmD, BCPS. Acute Care Pharmacist – Essentia Health Fargo. Disclosures. The presenter has nothing to disclose concerning possible financial or personal relationships with commercial entities (or their competitors) that may be referenced in this presentation..